Soleus Capital Master Fund, L.P. 13D and 13G filings for Rigel Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-11 4:00 pm Purchase |
2024-12-31 | 13G | Rigel Pharmaceuticals, Inc. RIGL |
Soleus Capital Master Fund, L.P. | 1,130,679 6.400% |
195,891 (+20.96%) |
Filing |
| 2024-11-14 3:33 pm Purchase |
2024-09-30 | 13G | Rigel Pharmaceuticals, Inc. RIGL |
Soleus Capital Master Fund, L.P. | 934,788 5.300% |
934,788 (New Position) |
Filing |